Saturday, July 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “combination”

418 pharma patents match "combination" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 418
Index total 30,257
Page 9 / 18

Quick answer

This filtered view shows 418 pharmaceutical patents matching "combination" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

418 results for “combination” · 30,257 patents in full index Clear search

  1. US 10786552

    Il-2Rβ-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 antibody

    Nektar Therapeutics · Granted Sep 29, 2020 · Expires Sep 24, 2040

    granted

  2. US 10780093

    Methods of treating brain tumors using combination therapy

    Agios Pharmaceuticals, Inc. · Granted Sep 22, 2020 · Expires Sep 17, 2040

    granted

  3. US 10765745

    Multifunctional nanoparticle systems and methods for cancer diagnosis and combination therapy

    The Board of Regents of the University of Texas System · Granted Sep 8, 2020 · Expires Sep 3, 2040

    granted

  4. US 10758614

    Combination therapies targeting tumor-associated stroma or tumor cells and topoisomerase

    THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH · Granted Sep 1, 2020 · Expires Aug 27, 2040

    granted

  5. US 10758526

    Combination therapies using agents that target tumor-associated stroma or tumor cells and other pathways

    THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH · Granted Sep 1, 2020 · Expires Aug 27, 2040

    granted

  6. US 10758613

    Combination therapies using anti-metabolites and agents that target tumor-associated stroma or tumor cells

    THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH · Granted Sep 1, 2020 · Expires Aug 27, 2040

    granted

  7. US 10729768

    Combination of anti-CD20 antibody and PI3 kinase selective inhibitor

    TG Therapeutics, Inc. · Granted Aug 4, 2020 · Expires Jul 30, 2040

    granted

  8. US 10716782

    LPT-723 and immune checkpoint inhibitor combinations and methods of treatment

    Biomed Valley Discoveries, Inc. · Granted Jul 21, 2020 · Expires Jul 16, 2040

    granted

  9. US 10695352

    Combination therapy for treating malignancies

    Agios Pharmaceuticals, Inc. · Granted Jun 30, 2020 · Expires Jun 25, 2040

    granted

  10. US 10688102

    Combination treatment for migraine and other pain

    AXSOME THERAPEUTICS, INC. · Granted Jun 23, 2020 · Expires Jun 18, 2040

    granted

  11. US 10688181

    Cancer treatment combinations

    The Regents of the University of California · Granted Jun 23, 2020 · Expires Jun 18, 2040

    granted

  12. US 10675288

    Natural combination hormone replacement formulations and therapies

    Compass Therapeutics LLC · Granted Jun 9, 2020 · Expires Jun 4, 2040

    granted

  13. US 10675304

    Combination immunotherapies for treatment of cancer

    PrimeVax Immuno-Oncology · Granted Jun 9, 2020 · Expires Jun 4, 2040

    granted

  14. US 10675302

    Methods and compositions for targeted cleavage and recombination

    Sangamo Therapeutics, Inc. · Granted Jun 9, 2020 · Expires Jun 4, 2040

    granted

  15. US 10668129

    Synergistic combination of neuronal viability factors and uses thereof

    The Regents of the University of California · Granted Jun 2, 2020 · Expires May 28, 2040

    granted

  16. US 10668055

    Cancer treatment using combinations of ERK and RAF inhibitors

    Biomed Valley Discoveries, Inc. · Granted Jun 2, 2020 · Expires May 28, 2040

    granted

  17. US 10653710

    Combination therapy for treating malignancies

    Agios Pharmaceuticals, Inc. · Granted May 19, 2020 · Expires May 14, 2040

    granted

  18. US 10653689

    Combination-based treatment method

    Nektar Therapeutics · Granted May 19, 2020 · Expires May 14, 2040

    granted

  19. US 10653789

    Polymer-drug conjugates for combination anticancer therapy

    The Regents of the University of California · Granted May 19, 2020 · Expires May 14, 2040

    granted

  20. US 10646523

    Combination comprising spirulina and palmitoylethanolamide and/or salts or pharmaceutically acceptable derivatives thereof and their formulations, for use in the prevention and/or in the treatment of hyperactivated tissue conditions

    AGAIN LIFE ITALIA SRL · Granted May 12, 2020 · Expires May 7, 2040

    granted

  21. US 10618967

    Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer

    Five Prime Therapeutics, Inc. · Granted Apr 14, 2020 · Expires Apr 9, 2040

    granted

  22. US 10610534

    Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency

    Corcept Therapeutics Incorporated · Granted Apr 7, 2020 · Expires Apr 2, 2040

    granted

  23. US 10583202

    Homologous recombination in multipotent adult progenitor cells

    Regents of the University of Minnesota · Granted Mar 10, 2020 · Expires Mar 5, 2040

    granted

  24. US 10583134

    Methods and therapeutic combinations for treating tumors

    The Board of Regents of the University of Texas · Granted Mar 10, 2020 · Expires Mar 5, 2040

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.